N/A N=810 Effectiveness of Differing Levels of Support for Family Mealtimes on Obesity Prevention Among Head Start Preschools
Obesity
Primary: Change in BMIz — .0060; .00027; .04; -.02 z-score — p=.34
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=47 Is it Feasible?: Self-Affirmation for Hereditary Breast and Ovarian Cancer Genetic Counseling
Breast Cancer
Primary: Test Uptake: Number of Clients Who Indicated Intention to Have Genetic Testing — 14; 15; 2; 0 Participants
Phase 2 N=44 A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer Metastatic
Primary: Objective Response Rate (ORR) — 32.5 percentage of participants
N/A N=30 Pilot of Mindfulness Oriented Recovery Enhancement in MethadoneTreatment
Opioid Use · Chronic Pain
Primary: Study Interest — 32 Participants
N/A N=274 A Public Health Intervention Program to Improve the Initial Management of Soft Tissue Sarcomas.
Sarcoma
Primary: Adherence Rate to Diagnosis Imaging Guidelines for Patients With a Deep Sarcoma Tumor (Before Implementation of the Public Health Intervention Programme. — 145…
N/A N=50 Computer - Controlled Intraligamentary Local Anaesthesia In Extraction of Primary Molars
Local Anaesthetic Drug Adverse Reaction
Primary: Baseline Heart Rate — 99.92; 98.80 beats per minute
Phase 3 N=682 Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAE) — 673; 527; 448; 575 Participants
N/A N=1,086 Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients
Secondary Immunodeficiencies (SID)
Primary: Guideline Adherence (GLAD) — 889; 75; 122 Participants
N/A N=62 Trial on Oral Appliance Design for Improving Upper Airway Function and Sleep Quality
Obstructive Sleep Apnea
Primary: Respiratory Event Index (REI) at T2 — 12.8; 21.1; 9.3; 13.1 number of events per hour — p=0.152
N/A N=164 Obesity Prevention in Head Start
Childhood Obesity
Primary: Change in Percentage of Children Over-consuming Energy During Lunch Attributable to Mealtime Matters — -10.9; -56.5 Percent of Participants
Phase 2 N=159 M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
Biliary Tract Cancer · Cholangiocarcinoma · Gallbladder Cancer
Primary: Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by…
N/A N=17 Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
Cognitive Impairment · Executive Dysfunction · Endothelial Dysfunction
Primary: Changes in Prefrontal Cortex Brain Activation at 6 Months — 90.64; -62.20; 28.07; -79.04 beta-weight
Phase 3 N=115 Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)
HIV Infections
Primary: Change From Baseline in the Acceptability of Intervention Measure (AIM) Total Score in Staff Study Participants at Month 4 — 0.00 Scores on a scale
Phase 1 N=53 Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors
Neoplasms
Primary: Number of Participants With Worst Grade 2 or Higher Adverse Events Occurring in >5% of Participants at Least Possibly Related to Study Drugs — 1; 0; 0; 0 Participants
Phase 2 N=396 A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia
COVID-19 Pneumonia
Primary: Time to Recovery, Defined as the Time to a Clinical Status Score of 1 or 2 on the 7-Category Ordinal Scale (Whichever Occurs First) by Day 28 — 10.0; 11.0; 10.0 Days…